Exchange & Returns Information
Review Details
(0)
| Generic For | PLATINOL |
|---|---|
| Active Ingredient | CISPLATIN |
| Strength | 50MG |
| Manufacturer | CIPLA |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 VIAL | $ 19.90 | $ 19.90 |
$ 16.92
Apply ZARVY26 (-15%)
You save $ 2.99
|
||
| 2 BOXES - 2 VIALS | $ 22.95 | $ 45.90 |
$ 39.02
Apply ZARVY26 (-15%)
You save $ 6.89
|
||
| ★ Best Value 3 BOXES - 3 VIALS | $ 23.63 | $ 70.90 |
$ 60.27
Apply ZARVY26 (-15%)
You save $ 10.64
|
Reference information will be available soon.
Cisplatin is a platinum-based chemotherapy drug that forms DNA crosslinks, interfering with replication and transcription. It induces apoptosis in rapidly dividing tumor cells and is a foundational agent in solid tumor chemotherapy regimens. Despite its toxicity, its broad clinical utility and proven efficacy make it a mainstay in oncology protocols worldwide.
AntiCancer Drugs > Non-Small Cell & Small Cell Lung Cancer (NSCLC & SCLC)
Used in platinum-doublet chemotherapy regimens to enhance the efficacy of radiation or targeted therapies.
Cervical Cancer
Standard radiosensitizing agent during concurrent chemoradiation (CCRT), increasing complete response rates.
Head and Neck Squamous Cell Carcinoma (HNSCC)
Used either alone or in combination (e.g., with 5-FU or Docetaxel) for patients with inoperable or recurrent disease.
Bladder Cancer
Core component of GC (Gemcitabine + Cisplatin) regimens for advanced or muscle-invasive bladder cancer.
Testicular Cancer
Essential in BEP (Bleomycin + Etoposide + Cisplatin) protocol, significantly improving cure rates for seminoma and non-seminoma germ cell tumors.
Ovarian, Gastric, Esophageal, Pancreatic, and Triple-Negative Breast Cancer
Employed in various neoadjuvant, adjuvant, or metastatic settings as part of combination regimens.
Platinum-based alkylating agent
Induces DNA crosslinking (inter- and intra-strand)
Inhibits DNA replication and transcription
Triggers cancer cell apoptosis
Testicular Cancer (Adults)
20 mg/m² IV infusion daily × 5 days per cycle
Administered as part of BEP regimen
Use: First-line therapy for advanced germ cell tumors
Ovarian Cancer (Adults)
75–100 mg/m² IV infusion on Day 1 every 3–4 weeks
Use: Standard combination chemotherapy for epithelial ovarian cancer
Bladder Cancer (Adults)
50–70 mg/m² IV infusion every 3–4 weeks
In heavily pretreated patients: 50 mg/m² every 4 weeks
Use: For locally advanced or metastatic urothelial carcinoma
Pediatric Use
Applied in pediatric testicular, ovarian, and bladder cancers
No standardized pediatric dosing; follow institutional protocol
Use: Under expert supervision as per cancer center guidelines
Store at temperatures below 25°C
Protect from light exposure
Do not refrigerate or freeze
Keep in original packaging until administration
Nephrotoxicity: Major dose-limiting toxicity; can cause renal tubular damage. Requires strict pre- and post-hydration protocols.
Ototoxicity: May lead to irreversible hearing loss, usually starting in the high-frequency range; risk increases with cumulative dose.
Severe nausea and vomiting: Highly emetogenic agent; always requires prophylactic antiemetic therapy.
Myelosuppression: Causes anemia, leukopenia, and thrombocytopenia, increasing the risk of infection and bleeding.
Peripheral neuropathy: Long-term use may result in tingling, numbness, or pain due to peripheral nerve damage.
Electrolyte imbalances: Particularly magnesium (Mg²⁺) and potassium (K⁺) loss, which may lead to muscle cramps or cardiac arrhythmias.
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
